Bristol-Myers Squibb Co vs Marathon Petroleum Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Marathon Petroleum Corp trades at $335.95 (market cap $94.48B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MPC | |
|---|---|---|
Market Cap | $129.94B | $94.48B |
Sector | Health | Energy |
52-Week High | $65.89 | $336.42 |
52-Week Low | $42.60 | $159.11 |
Enterprise Value | $163.92B | $121.00B |
Dividend Yield | 3.96% | 1.19% |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →